(NVCR) Novocure - NASDAQ
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 1.983m USD | Total Return: -0.7% in 12m
Avg Turnover: 23.6M
Qual. Beats: 0
Rev. Trend: 98.4%
Qual. Beats: 1
Warnings
Interest Coverage Ratio -10.4 is critical
Altman Z'' -2.60 < 1.0 - financial distress zone
Choppy
Tailwinds
No distinct edge detected
NovoCure Limited is a Swiss-based oncology company specializing in the development and commercialization of Tumor Treating Fields (TTFields) technology. This proprietary therapy uses electric fields tuned to specific frequencies to disrupt cancer cell division in solid tumors. The company currently markets devices including Optune Gio and Optune Lua for indications such as glioblastoma and malignant pleural mesothelioma.
Operating within the healthcare equipment sector, NovoCure utilizes a medical device-as-a-service business model, generating recurring revenue through monthly patient prescriptions rather than one-time hardware sales. The firm maintains an extensive clinical pipeline, targeting highly prevalent malignancies including non-small cell lung, pancreatic, and gastric cancers to expand its addressable market.
Investors looking for deeper financial metrics and peer comparisons should consult ValueRay to broaden their analysis. NovoCure continues to manage international operations across major markets in North America, Europe, and Asia while awaiting results from several late-stage clinical trials.
- FDA approval and commercial launch for non-small cell lung cancer
- Clinical trial data readouts for pancreatic and ovarian cancer indications
- Optune Gio adoption rates and reimbursement coverage in international markets
- Research and development spending levels impact path to sustained profitability
| Net Income: -173.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.06 > 0.02 and ΔFCF/TA -0.32 > 1.0 |
| NWC/Revenue: 61.40% < 20% (prev 55.65%; Δ 5.75% < -1%) |
| CFO/TA -0.03 > 3% & CFO -26.9m > Net Income -173.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (114.1m) vs 12m ago 3.51% < -2% |
| Gross Margin: 75.20% > 18% (prev 77.16%; Δ -1.96% > 0.5%) |
| Asset Turnover: 66.23% > 50% (prev 49.78%; Δ 16.44% > 0%) |
| Interest Coverage Ratio: -10.44 > 6 (EBIT TTM -177.9m / Interest Expense TTM 17.0m) |
| A: 0.53 (Total Current Assets 631.7m - Total Current Liabilities 217.6m) / Total Assets 787.9m |
| B: -1.73 (Retained Earnings -1.36b / Total Assets 787.9m) |
| C: -0.17 (EBIT TTM -177.9m / Avg Total Assets 1.02b) |
| D: 0.72 (Book Value of Equity 330.7m / Total Liabilities 457.2m) |
| Altman-Z'' = -2.60 = D |
| DSRI: 0.73 (Receivables 93.3m/118.5m, Revenue 674.4m/621.7m) |
| GMI: 1.03 (GM 77.16% / 75.20%) |
| AQI: 1.23 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 1.08 (Revenue 674.4m / 621.7m) |
| TATA: -0.19 (NI -173.0m - CFO -26.9m) / TA 787.9m) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of June 15, 2026, the stock is trading at USD 17.78 with a total of 990,221 shares traded.
Over the past week, the price has changed by +3.61%,
over one month by -1.50%,
over three months by +43.62% and
over the past year by -0.70%.
Novocure has received a consensus analysts rating of 4.14. Therefore, it is recommended to buy NVCR.
- StrongBuy: 3
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 26.3 | 47.9% |
P/E Forward = 909.0909
P/S = 2.941
P/B = 4.4951
P/EG = -0.47
Revenue TTM = 674.4m USD
EBIT TTM = -177.9m USD
EBITDA TTM = -159.9m USD
Long Term Debt = 195.5m USD (from longTermDebt, last quarter)
Short Term Debt = 11.7m USD (from shortTermDebt, last fiscal year)
Debt = 274.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 39.5m
Net Debt = -167.4m USD (calculated: Debt 274.4m - CCE 441.8m)
Enterprise Value = 1.82b USD (1.98b + Debt 274.4m - CCE 441.8m)
Interest Coverage Ratio = -10.44 (Ebit TTM -177.9m / Interest Expense TTM 17.0m)
EV/FCF = -37.78x (Enterprise Value 1.82b / FCF TTM -48.1m)
FCF Yield = -2.65% (FCF TTM -48.1m / Enterprise Value 1.82b)
FCF Margin = -7.13% (FCF TTM -48.1m / Revenue TTM 674.4m)
Net Margin = -25.66% (Net Income TTM -173.0m / Revenue TTM 674.4m)
Gross Margin = 75.20% ((Revenue TTM 674.4m - Cost of Revenue TTM 167.3m) / Revenue TTM)
Gross Margin QoQ = 77.63% (prev 75.82%)
Tobins Q-Ratio = 2.30 (Enterprise Value 1.82b / Total Assets 787.9m)
Interest Expense / Debt = 6.21% (Interest Expense 17.0m / Debt 274.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -140.6m (EBIT -177.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.90 (Total Current Assets 631.7m / Total Current Liabilities 217.6m)
Debt / Equity = 0.83 (Debt 274.4m / totalStockholderEquity, last quarter 330.7m)
Debt / EBITDA = 1.05 (negative EBITDA) (Net Debt -167.4m / EBITDA -159.9m)
Debt / FCF = 3.48 (negative FCF - burning cash) (Net Debt -167.4m / FCF TTM -48.1m)
Total Stockholder Equity = 340.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -16.99% (Net Income -173.0m / Total Assets 787.9m)
RoE = -50.82% (Net Income TTM -173.0m / Total Stockholder Equity 340.5m)
RoCE = -33.20% (EBIT -177.9m / Capital Employed (Equity 340.5m + L.T.Debt 195.5m))
RoIC = -25.64% (negative operating profit) (NOPAT -140.6m / Invested Capital 548.3m)
WACC = 10.88% (E(1.98b)/V(2.26b) * Re(11.71%) + D(274.4m)/V(2.26b) * Rd(6.21%) * (1-Tc(0.21)))
Discount Rate = 11.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 2.92%
[DCF] Fair Price = unknown (Cash Flow -48.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.83 | # QB: 0
Revenue Correlation: 98.37 | Revenue CAGR: 12.52% | SUE: 1.28 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.33 | Chg30d=+9.69% | Revisions=+27% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.33 | Chg30d=+2.56% | Revisions=+11% | Analysts=7
EPS current Year (2026-12-31): EPS=-1.59 | Chg30d=-3.82% | Revisions=-20% | GrowthEPS=-30.7% | GrowthRev=+7.4%
EPS next Year (2027-12-31): EPS=-1.17 | Chg30d=-0.49% | Revisions=-9% | GrowthEPS=+26.5% | GrowthRev=+10.4%
[Analyst] Revisions Ratio: +27%